North America Internal Neurostimulation Devices Market
市场规模(十亿美元)
CAGR :
%
USD
2.76 Billion
USD
12.26 Billion
2025
2033
| 2026 –2033 | |
| USD 2.76 Billion | |
| USD 12.26 Billion | |
|
|
|
|
北美内部神经刺激装置市场,按产品类型(脊髓硬化刺激(SCS)、深脑刺激、真空神经刺激、皮肤神经刺激和胃电刺激)、铅类型(皮层和平板铅)、生物材料(金属、聚合和陶瓷)、分销渠道(直接招标和第三方服务提供者)- 2033年工业趋势和预测
北美内部神经刺激设备市场概况
北美内部神经刺激装置市场价值2025年27.6亿美元预计将达到到2033年122.6亿美元,生长在一个2026-2033年CAGR为20.5%市场正在经历强劲增长,其驱动力是:神经系统紊乱现象日益普遍;越来越多地采用最低侵入性疼痛管理疗法;以及可植入神经刺激系统持续技术进步。
慢性疼痛、帕金森病、癫痫和整个区域的运动紊乱等日益加重的负担,再加上老年人口的扩大和医疗支出的增加,正在加速对先进神经刺激解决方案的需求。 保健提供者和研究机构越来越多地采用脊髓刺激、深脑刺激和活泼神经刺激装置,因为这些装置在长期症状管理和改善病人结果方面行之有效。 此外,有利的偿还政策、主要医疗器械制造商的强大存在、以及可充电和与核磁共振相容植入方面的持续创新,进一步支持了美国和加拿大各地的市场扩张。
主要市场趋势和见解
- 美国主导了北美内部神经刺激装置市场,2025年收入份额最大,为84.63%,得到了先进的保健基础设施、高水平采用可植入神经调节技术以及优惠的偿还政策的支持。
- 由慢性疼痛紊乱症发病率上升所推动,脊髓硬化刺激(SCS)部分在2025年以38.74%的比重带动了市场,背部手术综合征失败,整个北美出现神经病痛状况.
- 2026年至2033年,加拿大的CAGR增长最快,为21.1%,而神经紊乱病例增多、保健投资扩大、对神经刺激治疗的认识得到提高。
- 深脑刺激是增长最快的产品类型,预计CAGR为22.1%,反映了帕金森病、基本颤抖、癫痫和运动紊乱的发病率激增。
- 2025年,皮层铅部分占了铅类的主导地位,收入份额为61.42%,由入侵性最小的植入程序、较短的恢复期和与桨式铅系统相比的外科复杂程度所领导。
- 金属占市场52.83%,更受优秀的电导性、耐久性和可植入神经刺激系统中的生物相容性的影响。
- Polymeric分系是生长最快的生物材料类,CAGR为22.8%,由先进神经刺激系统中对轻量级,弹性和生物相容的植入材料日益增长的需求所驱动.
市场大小和预测
- 全球市场价值(2025):276亿美元
- (2033年):12.26亿美元
- CAGR(2026-2033年):20.5%
- 2025年主要国家:美国
- 最快增长的国家:加拿大
报告范围和范围北美内部神经刺激设备市场分割
|
属性 |
北美内部神经刺激设备键市场透视 |
|
覆盖部分 |
|
|
涵盖国家 |
北美 · 美国。 加拿大 墨西哥 |
|
关键市场玩家 |
• 妇女美敦力克(爱尔兰) • 妇女阿博特(签名)(美国). • 妇女波士顿科学公司(美国). • 妇女涅夫罗公司(美国). • 妇女利瓦诺瓦PLC(吴. 集成控股公司(美国) • 突发生物医学公司(美国) · 电子Core公司(美国) · Neurosigma公司(美国) Nalu医疗公司(美国) Biotronik SE & Co. KG (德国) • Cirtec医疗公司(美国) • Neuropace公司(美国) Axonics股份有限公司(美国) * 主营医疗控股(爱尔兰) 卡拉健康公司(美国) Saluda医药有限公司(澳大利亚) Aleva Neurothemeutics SA(瑞士) · 场景有限公司(中国) · 微型运输公司(美国) |
|
市场机会 |
越来越多地采用闭路和人工智能辅助神经刺激系统 · 扩大对最低侵入性和无阿片止痛疗法的需求 在抑郁症、癫痫症和运动障碍中神经刺激应用的临床研究和FDA批准增加 |
|
添加数据信息集的值 |
除了对市场价值、增长率、分割、地理覆盖和主要角色等市场假设的深刻见解外,由数据桥市场研究编写的市场报告还包括深入的专家分析、病人流行病学、管道分析、定价分析和监管框架。 |
北美内部神经刺激装置市场趋势
趋势:逐步采用闭环和智能神经刺激系统
保健提供者和医疗器械制造商越来越多地采用闭眼神经刺激系统,以提高治疗精度,使治疗交付个性化,并增强慢性神经疾病患者的长期结果。 AI辅助编程,无线连接,以及实时神经信号监测的整合,使医生能够根据病人的反应和疾病发展来优化刺激环境. 医院和专科神经科中心同样正在部署先进的可植入装置来改进慢性疼痛管理、运动障碍治疗和癫痫护理,而核磁共振兼容技术则能加强病人的安全,并在整个不同的保健环境中扩大临床可用性。
例如,2025年1月,Medtronic扩大了其在北美的适应性深脑刺激平台组合,支持个性化疗法的提供和先进的神经紊乱管理能力.
北美内部神经刺激设备市场动态
关键市场驱动器:增加对最小侵入神经疾病治疗的需求
慢性疼痛、帕金森病、癫痫和运动紊乱的发病率不断上升,大大增加了对能够提供目标明确和最低侵入性疗法解决方案的可植入神经刺激装置的需求。 保健提供者、神经学专家和康复中心越来越多地采用脊髓刺激、脑深刺激和活泼神经刺激系统,以减少对以阿片类药物为基础的治疗的依赖,改善患者的康复结果并支助长期疾病管理。 在可充电植入物、无线编程平台和核磁共振兼容装置方面持续技术进步,正在进一步加快整个北美的医院和专科诊所的采用。
例如,2025年3月,Abbott Laboratories为慢性疼痛治疗引入了强化神经刺激编程功能,提高了各种临床环境的治疗定制和病人监测效率.
关键限制/挑战:可植入神经刺激程序的成本高而复杂
北美内部神经刺激装置市场的一个主要制约因素是,与先进的可植入神经调节疗法和长期病人管理要求有关的程序和装置相关费用高昂。 现代神经刺激系统整合了精密可移植脉冲发电机,可充电电池,无线编程接口,和精密电极,导致手术植入,维护,程序后监测等大量费用. 总体治疗负担还包括临床跟踪、更换电池手术和报销限制,这使得在某些地区市场对成本敏感的保健提供者和没有保险的病人群体进行治疗具有挑战性。
例如,在2024年9月,波士顿科学公司在北美扩展其神经调节产品组合期间,强调了与先进脊髓刺激系统有关的业务和植入成本不断上升。
主要市场机会:扩大慢性疼痛管理之外的神经刺激应用
在整个精神障碍、癫痫、中风康复和运动障碍治疗中扩大对神经刺激技术的临床应用,为北美市场提供了巨大的增长机会。 先进的神经调节平台可以支持个性化的神经疗法,改善认知康复结果,并能够对以前服务不足的病人群体采取有针对性的刺激方法. AI辅助疗法优化,远程患者监测系统,下一代生物电子医学技术的发展,使全区医院,专科诊所,神经学研究机构的商业化机会进一步扩大. 例如,在2025年2月,LivaNova PLC扩大了针对整个北美保健网络神经和精神障碍的活性神经刺激疗法的临床研究举措。
北美内部神经刺激装置市场范围
北美内部神经刺激装置市场根据产品类型,铅类型,生物材料,以及分出渠道进行分化.
- 按产品类型
根据产品类型,北美内部神经刺激装置市场被分入脊髓刺激(SCS),深脑刺激,活泼神经刺激,圣神经刺激,和胃电刺激. 2025年,由慢性疼痛紊乱症发病率上升、背部手术综合征失败以及整个北美的神经病痛状况所驱动,脊髓硬化刺激(SCS)部分以38.74%的收入份额支配了市场。 SCS系统之所以被广泛采用,是因为其经证明在疼痛管理方面具有长期效力并减少了对以类阿片为基础的疗法的依赖。 越来越偏好最低侵入性治疗程序,对神经调节疗法的认识也越来越高,这进一步支持了分块增长。 可充电可移植脉冲发电机、无线编程技术和核磁共振兼容系统的持续进步正在提高病人的结果和治疗效率。 医院和专科疼痛管理诊所越来越多地将先进的SCS设备纳入慢性神经病的治疗规程. 整个美国和加拿大的优惠偿还范围和强有力的监管批准继续加强了这一部门的主导地位。
由于帕金森病、基本颤抖、癫痫和运动紊乱的发病率不断上升,2026年至2033年的CAGR增长22.1%,深度脑刺激部分预计增长最快。 DBS系统向特定大脑区域提供有针对性的电刺激,改善症状管理和患者生活质量. 老年人口的增长和神经疾病负担的上升正在大大加快对先进神经刺激疗法的需求。 适应性刺激平台,闭路系统,AI辅助编程的技术进步,正在进一步提高治疗精度和安全性. 增加临床研究活动和扩大经FDA批准的神经征兆也促进了分块生长. 预计主要医疗器械制造商对创新神经调节技术的投资将进一步支持整个北美的快速采用。
- 按铅类型
根据铅类型,北美内部神经刺激装置市场被分解成皮下和桨状铅. 2025年,由于植入程序极少侵入,恢复期较短,手术复杂程度低于桨式铅系统,因此皮层铅部分在市场上占有61.42%的份额。 这些线索因其灵活性、降低程序风险和成本效益而被广泛用于脊髓刺激程序。 提供保健服务者越来越倾向于用近缘线索进行门诊神经刺激程序和慢性疼痛管理应用。 铅耐久性,刺激精度,多接触电极配置的持续进步,进一步提高了临床性能. 北美各地流动外科中心和最低侵入性神经调节程序的数量不断增加,这正在加强分区的采用。 有利的报销支助和病人对较少侵入性治疗选择的更偏好继续支持这一部分的主导地位。
Paddle铅部分预计将在2026年至2033年21.7%的CAGR增长最快,其驱动力在于其较高的刺激稳定性、较低的铅迁移风险以及增强的长期治疗效果。 平板铅能提供更广泛和更有针对性的刺激覆盖,使其非常适合复杂的慢性疼痛和神经紊乱管理. 先进脊髓刺激程序日益采用,对长期神经调节疗法的需求也日益增加,这些都有助于市场增长。 外科植入技术和成像制导程序的技术改进正在减少与桨铅有关的程序并发症。 医院和专科神经医学中心越来越多地为需要更高刺激精度和耐久临床结果的病人采用这些系统。 日益重视提高治疗可靠性和病人的满意度,预计会进一步加快部分扩展。
- 生物物质
在生物材料的基础上,北美内部神经刺激装置市场被分解为金属,聚合物和陶瓷. 金属部分在2025年占市场份额最高,为52.83%,原因是其出色的电导性、耐久性和可植入神经刺激系统中的生物相容性。 金属材料因其可靠性和操作寿命长而被广泛用于电极、连接器和可移植脉冲发生器组件。 在脊髓刺激和深脑刺激应用中,对高性能可植入装置的需求日益增加,这支持了部分生长。 抗腐蚀合金和小型植入技术的持续进步正在进一步提高产品效率和病人的安全性。 医疗器械制造商正在对先进的金属生物材料进行大量投资,以提高设备耐久性并降低植入故障率. 整个北美保健设施的严格监管接受和广泛临床使用继续强化了这一部门的支配地位。
由先进神经刺激系统对轻量级、弹性和生物相容性植入材料的需求增加所驱动,预计在2026年至2033年的CAGR增长22.8%时,Polymeric分会最快。 聚物材料由于适应性和病人舒适性得到提高,越来越多地被用于隔热涂层、弹性铅和下一代可植入装置组件。 生物可逆聚合物和智能生物材料技术方面的进步正在扩大其适用于神经调节疗法的范围。 日益重视小型和可灵活植入的装置,正在进一步加速采用分部件。 研究机构和医疗器械公司正积极投资创新的以聚合物为基础的神经刺激平台,以提高长期植入安全性和治疗有效性. 预计对方便病人和最低侵入性神经刺激技术的需求将进一步支持快速分块增长。
- 按发行频道
北美内部神经刺激器件市场在分出渠道的基础上被分出为直接招标和第三方服务供应商. 2025年,由于整个北美的保健机构和神经刺激设备制造商之间建立了强有力的采购伙伴关系,直接招标部分在市场上占有68.14%的收入份额。 大型医院、专业神经中心和政府保健设施越来越多地直接从制造商那里采购神经刺激系统,以确保产品的真实性、技术支持和成本效益。 直接采购渠道也使保健提供者能够获得定制的服务协议、培训方案和长期维修支助。 先进神经调节程序的数量不断增加,对医院基础设施的投资也不断增加,这都加强了部分需求。 主要市场参与者正注重扩大直接销售网络和与保健提供者的战略合作,以改善产品的可获得性。 强有力的偿还框架和集中采购系统继续支持直接投标部分占主导地位。
第三方服务提供者部分预计将以2026至2033年20.9%的CAGR增长最快,原因是医疗器械分配、技术服务和植入后支助活动的外包增加。 较小的保健设施和流动外科中心越来越依赖第三方经销商来改善先进神经刺激系统的使用和降低业务费用。 这些服务提供者提供灵活的后勤、设备维修和库存管理解决方案,以提高提供保健服务的效率。 越来越多地采用家庭式病人监测和远程神经刺激管理服务,也正在支持扩大部分。 医疗器械制造商与区域分销供应商之间日益加强的伙伴关系,正在改善服务不足市场的产品渗透率。 预计对成本效益高的分配和技术支助解决办法的需求将进一步加快整个北美这一部分的增长。
北美内部神经刺激装置市场区域分析
美国主导了北美内部神经刺激装置市场,2025年收入份额最大,为84.63%,得到了先进的保健基础设施、高水平采用可植入神经调节技术以及优惠的偿还政策的支持。 该国还受益于优惠的报销政策,慢性疼痛和神经疾病日益普遍,以及医院和专科诊所越来越多地采用最低侵入性神经刺激程序。 研发投资不断增加,可充电和核磁共振兼容设备不断进步,慢性疼痛、癫痫和运动紊乱管理方面的临床应用不断扩大,这继续强化了美国在区域市场的领导地位。
美国北美内部神经刺激设备市场透视
美国内部神经刺激器械市场由于慢性疼痛障碍的日益流行,越来越多地采用最低侵入性神经调节疗法,以及对神经治疗技术的大力投资而出现强劲增长. 国内先进的医疗基础设施、有利的报销框架、以及主要医疗器械制造商的强大存在正在推动医院、专科诊所和研究机构的需求。 此外,美国各地越来越注重减少阿片依赖性,并改进长期神经紊乱管理,正在加速采用脊髓刺激、脑深刺激和活泼神经刺激系统。
加拿大内部神经刺激设备市场透视
加拿大内部神经刺激装置市场正在稳步增长,神经系统紊乱病例增加、保健支出增加以及越来越多地采用先进的神经调节疗法。 医院和专科神经医学中心越来越多地利用可植入的神经刺激装置进行慢性疼痛管理、癫痫治疗和运动障碍疗法。 人们对尽量减少侵入性治疗办法的认识日益提高,政府采取了有利的保健举措并扩大了获得先进医疗技术的机会,这进一步推动了市场的扩大。 在可充电植入、核磁共振兼容系统和无线编程技术方面的持续进步也支持加拿大各地增加采用。
墨西哥内部神经刺激设备市场透视
墨西哥内部神经刺激装置市场由于改善保健基础设施、提高对神经系统紊乱症治疗的认识和越来越多地采用最低侵入性医疗技术而逐步增长。 保健提供者和专科诊所越来越多地将神经刺激装置用于慢性疼痛管理和运动障碍治疗。 对保健现代化、扩大获得先进神经护理的机会和对成本效益高的治疗办法的需求日益增加的投资正在支持市场发展。 此外,医疗器械制造商和区域保健机构之间不断加强的协作,有助于在墨西哥各地采用内部神经刺激器械。
北美内部神经刺激设备市场份额
北美内部神经刺激装置行业主要由地位良好的公司领导,包括:
- 梅德罗尼克(爱尔兰)
- 阿博特 (美国).
- 波士顿科学公司(美国)
- Nevro公司(美国)
- Liva Nova PLC (英国).
- 集成控股公司(美国)
- 突触生物医学公司(美国)
- 电子Core股份有限公司(美国)
- Neurosigma股份有限公司(美国)
- 纳鲁医疗股份有限公司(美国)
- Biotronik SE & Co. KG(德国)
- Cirtec医疗公司(美国)
- Neuropace公司(美国)
- Axonics股份有限公司(美国)
- 主营医疗控股(爱尔兰)
- 卡拉健康股份有限公司(美国)
- 萨卢达医药有限公司(澳大利亚)
- Aleva Neuropheutics SA(瑞士)
- 场景股份有限公司(中国)
- MicroTransponder公司(美国)
北美最新动态 内部神经刺激设备市场
- 2025年10月,波士顿科学公司宣布收购Nalu Medical,以扩大其慢性疼痛和外围神经刺激组合. Nalu Medical的小型神经刺激技术通过无电池的可植入脉冲发电机通过外部系统进行无线控制,提供针对性的止痛. 收购加强了波士顿科学公司的神经调节能力,并扩大了对各地慢性疼痛患者的先进神经刺激疗法的普及范围。
- 2025年5月,Stryker Corporation宣布FDA批准其OptaBlate® BVN Basivertebral Nerve Ablation System,旨在治疗慢性脊椎低背痛. 入侵性最小的平台扩展了Stryker的高级疼痛治疗组合,并强化了其在神经调节相关疼痛管理技术中的地位. 启动表明,北美工业界日益重视针对慢性疼痛治疗的神经调节程序
- Medtronic于2025年2月宣布美国FDA批准其用于帕金森疾病管理的BrainSenseTM适应性深脑刺激(aDBS)系统. 该系统根据患者的脑活性自动调整刺激,改善治疗个性化和症状控制. 这次发射标志着大脑-计算机接口技术在神经学护理中的最大商业部署之一,并强化了美敦尼克在北美各地的神经调节组合.
- 2024年5月,Abbott Laboratories获得美国FDA批准,在其脊髓硬化刺激(SCS)系统组合中,包括Prolection XR和Eterna平台,扩展了标识. 批准支持更广泛的慢性疼痛管理应用,并强化了Abbott在可植入神经调节技术中的地位. 开发工作还通过先进的编程和可充电设备能力,提高了长期处理的灵活性
- 2024年1月,Medtronic因其与BrainSenseTM技术相融合的PereptTM RC可充电深脑刺激神经刺激器而获得了FDA的批准. 该设备能够使感能化的DBS疗法具有实时神经信号监测和运动障碍患者个性化编程能力. 发射扩大了Medtronic的可充电神经刺激组合,加强了美国市场对适应性神经调节系统的采用
SKU-
目录
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHIC SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 RESEARCH METHODOLOGY
2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.7 DBMR MARKET POSITION GRID
2.8 THE CATEGORY VS TIME GRID
2.9 SECONDARY SOURCES
2.1 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL
4.2 PORTER'S FIVE FORCES MODEL
4.3 PIPELINE ANALYSIS FOR INTERNAL NEUROSTIMULATION DEVICES MARKET
5 REGULATIONS OF NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET
6 EPIDEMIOLOGY OF DISEASES
6.1 INCIDENCE OF ISCHEMIA
6.2 INCIDENCE OF PARKINSON'S DISEASE
6.3 INCIDENCE OF FAILED BACK SYNDROME
6.4 INCIDENCE OF TREMOR
6.5 INCIDENCE OF DEPRESSION
6.6 INCIDENCE OF URINE INCONTINENCE
6.7 INCIDENCE OF FECAL INCONTINENCE
6.8 INCIDENCE RATE OF EPILEPSY
6.9 INCIDENCE OF GASTROPARESIS
6.1 PREVALENCE OF OBESITY
7 EPIDEMIOLOGY OF NEUROSTIMULATION PROCEDURES
7.1 NUMBER OF SPINAL CORD STIMULATION (SCS) PROCEDURES
7.1.1 NUMBER OF TEST PROCEDURES
7.1.2 NUMBER OF IMPLANTATION PROCEDURES
7.2 NUMBER OF DEEP BRAIN STIMULATION PROCEDURES
7.3 NUMBER OF VAGUS NERVE STIMULATION PROCEDURES
7.4 NUMBER OF SACRAL NEVER STIMULATION PROCEDURES
7.5 NUMBER OF TRANSCRANIAL MAGNETIC STIMULATION (TMS) PROCEDURES
7.6 NUMBER OF INTERMITTENT THETA BURST STIMULATION (ITBS) PROCEDURES
7.7 NUMBER OF TRANSCRANIAL DIRECT ELECTRICAL STIMULATION (TDCS) PROCEDURES
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 RISE IN PREVALENCE AND INCIDENCE OF NEUROLOGICAL DISORDERS
8.1.2 DEMAND FOR INTERNAL NEUROSTIMULATION DEVICES AS A ADD ON THERAPY
8.1.3 INCREASED FUNDING FOR THE NEUROSTIMULATION DEVICES
8.1.4 TECHNOLOGICAL ADVANCEMENTS IN THE INTERNAL NEUROSTIMULATION DEVICES
8.1.5 RISE IN PRODUCT APPROVALS
8.2 RESTRAINTS
8.2.1 RISE IN COST OF THE DEEP BRAIN STIMULATION DEVICES
8.2.2 RISKS NOTICED WHILE USING THE INTERNAL NEUROSTIMULATION DEVICES
8.2.3 RISE IN PRODUCT RECALL
8.2.4 AVAILABILITY OF ALTERNATE IMAGING DIAGNOSTIC DEVICES
8.3 OPPORTUNITIES
8.3.1 STRATEGIC INITIATIVES BY THE KEY MARKET PLAYER
8.3.2 RECENT PRODUCT DEVELOPMENTS IN THE INTERNAL NEUROSTIMULATION DEVICES
8.3.3 DEMAND FOR MINIMALLY INVASIVE SURGERY
8.4 CHALLENGES
8.4.1 RISKS ASSOCIATED WITH THE IMPLANTATION OF THESE DEVICES
8.4.2 LACK OF SKILLED HEALTHCARE PROFESSIONALS
9 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE
9.1 OVERVIEW
9.2 SPINAL CORD STIMULATION
9.2.1 SPINAL CORD STIMULATION, BY TYPE
9.2.1.1 BATTERY
9.2.1.1.1 RECHARGEABLE
9.2.1.1.2 NON-RECHARGEABLE
9.2.1.2 LEAD
9.2.1.2.1 PERCUTANEOUS
9.2.1.2.2 PADDLE
9.2.2 SPINAL CORD STIMULATION, BY APPLICATION
9.2.2.1 ISCHEMIA
9.2.2.2 CHRONIC LOW BACK PAIN (CLBP)
9.2.2.3 DIABETIC NEUROPATHY
9.2.2.4 FAILED BACK SYNDROME
9.3 DEEP BRAIN STIMULATION
9.3.1 DEEP BRAIN STIMULATION, BY TYPE
9.3.1.1 SINGLE CHANNEL DEEP BRAIN STIMULATOR
9.3.1.2 DOUBLE CHANNEL DEEP BRAIN STIMULATOR
9.3.1.3 BATTERY
9.3.1.3.1 RECHARGEABLE
9.3.1.3.2 NON-RECHARGEABLE
9.3.1.4 LEAD
9.3.2 DEEP BRAIN STIMULATION, BY APPLICATION
9.3.2.1 PARKINSON’S DISEASE
9.3.2.2 TREMOR
9.3.2.3 DEPRESSION
9.4 SACRAL NERVE STIMULATION
9.4.1 SACRAL NERVE STIMULATION, BY TYPE
9.4.1.1 BATTERY
9.4.1.2 LEAD
9.5 SACRAL NERVE STIMULATION, BY APPLICATION
9.5.1 URINE INCONTINENCE
9.5.2 FECAL INCONTINENCE
9.6 VAGUS NERVE STIMULATION
9.6.1 VAGUS NERVE STIMULATION, BY TYPE
9.6.1.1 BATTERY
9.6.1.2 LEAD
9.6.2 VAGUS NERVE STIMULATION, BY APPLICATION
9.6.2.1 EPILEPSY
9.6.2.2 OTHERS
9.7 GASTRIC ELECTRICAL STIMULATION
9.7.1 GASTRIC ELECTRICAL STIMULATION, BY TYPE
9.7.1.1 BATTERY
9.7.1.2 LEAD
9.7.2 GASTRIC ELECTRICAL STIMULATION, BY APPLICATION
9.7.2.1 GASTROPARESIS
9.7.2.2 OTHERS
10 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL
10.1 OVERVIEW
10.2 DIRECT TENDER
10.3 THIRD PARTY PROVIDER
11 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY REGION
11.1 NORTH AMERICA
11.1.1 U.S.
11.1.2 CANADA
11.1.3 MEXICO
12 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: COMPANY LANDSCAPE
12.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
13 SWOT ANALYSIS
14 COMPANY PROFILE
14.1 MEDTRONIC (2021)
14.1.1 COMPANY SNAPSHOT
14.1.2 REVENUE ANALYSIS
14.1.3 COMPANY SHARE ANALYSIS
14.1.4 PRODUCT PORTFOLIO
14.1.5 RECENT DEVELOPMENTS
14.2 BOSTON SCIENTIFIC CORPORATION (2021)
14.2.1 COMPANY SNAPSHOT
14.2.2 REVENUE ANALYSIS
14.2.3 COMPANY SHARE ANALYSIS
14.2.4 PRODUCT PORTFOLIO
14.2.5 RECENT DEVELOPMENTS
14.3 ABBOTT (2021)
14.3.1 COMPANY SNAPSHOT
14.3.2 REVENUE ANALYSIS
14.3.3 COMPANY SHARE ANALYSIS
14.3.4 PRODUCT PORTFOLIO
14.3.5 RECENT DEVELOPMENTS
14.4 LIVANOVA PLC (2021)
14.4.1 COMPANY SNAPSHOT
14.4.2 REVENUE ANALYSIS
14.4.3 COMPANY SHARE ANALYSIS
14.4.4 PRODUCT PORTFOLIO
14.4.5 RECENT DEVELOPMENTS
14.5 NEVRO CORP. (2021)
14.5.1 COMPANY SNAPSHOT
14.5.2 REVENUE ANALYSIS
14.5.3 COMPANY SHARE ANALYSIS
14.5.4 PRODUCT PORTFOLIO
14.5.5 RECENT DEVELOPMENTS
14.6 AXONICS, INC.
14.6.1 COMPANY SNAPSHOT
14.6.2 REVENUE ANALYSIS
14.6.3 PRODUCT PORTFOLIO
14.6.4 RECENT DEVELOPMENTS
14.7 ALEVA NEUROTHERAPEUTICS
14.7.1 COMPANY SNAPSHOT
14.7.2 PRODUCT PORTFOLIO
14.7.3 RECENT DEVELOPMENTS
14.8 BIONIC VISION TECHNOLOGIES.
14.8.1 COMPANY SNAPSHOT
14.8.2 PRODUCT PORTFOLIO
14.8.3 RECENT DEVELOPMENTS
14.9 BLUEWIND MEDICAL
14.9.1 COMPANY SNAPSHOT
14.9.2 PRODUCT PORTFOLIO
14.9.3 RECENT DEVELOPMENTS
14.1 BIOINDUCTION
14.10.1 COMPANY SNAPSHOT
14.10.2 PRODUCT PORTFOLIO
14.10.3 RECENT DEVELOPMENT
14.11 CIRTEC
14.11.1 COMPANY SNAPSHOT
14.11.2 PRODUCT PORTFOLIO
14.11.3 RECENT DEVELOPMENTS
14.12 FINETECH MEDICAL
14.12.1 COMPANY SNAPSHOT
14.12.2 PRODUCT PORTFOLIO
14.12.3 RECENT DEVELOPMENTS
14.13 GIMER MEDICAL
14.13.1 COMPANY SNAPSHOT
14.13.2 PRODUCT PORTFOLIO
14.13.3 RECENT DEVELOPMENTS
14.14 INSPIRE MEDICAL SYSTEMS, INC.
14.14.1 COMPANY SNAPSHOT
14.14.2 REVENUE ANALYSIS
14.14.3 PRODUCT PORTFOLIO
14.14.4 RECENT DEVELOPMENTS
14.15 INTEGER HOLDINGS CORPORATION
14.15.1 COMPANY SNAPSHOT
14.15.2 REVENUE ANALYSIS
14.15.3 PRODUCT PORTFOLIO
14.15.4 RECENT DEVELOPMENT
14.16 INBRAIN NEUROELECTRONICS
14.16.1 COMPANY SNAPSHOT
14.16.2 PRODUCT PORTFOLIO
14.16.3 RECENT DEVELOPMENT
14.17 MAINSTAY MEDICAL
14.17.1 COMPANY SNAPSHOT
14.17.2 REVENUE ANALYSIS
14.17.3 PRODUCT PORTFOLIO
14.17.4 RECENT DEVELOPMENTS
14.18 MICROSEMI (A WHOLLY OWNDED SUBSIDIARY OF MICROCHIP TECHNOLOGY INC.)
14.18.1 COMPANY SNAPSHOT
14.18.2 REVENUE ANALYSIS
14.18.3 PRODUCT PORTFOLIO
14.18.4 RECENT DEVELOPMENTS
14.19 MICROTRANSPONDER INC
14.19.1 COMPANY SNAPSHOT
14.19.2 PRODUCT PORTFOLIO
14.19.3 RECENT DEVELOPMENT
14.2 MICRO-LEADS
14.20.1 COMPANY SNAPSHOT
14.20.2 PRODUCT PORTFOLIO
14.20.3 RECENT DEVELOPMENT
14.21 NALU MEDICAL, INC
14.21.1 COMPANY SNAPSHOT
14.21.2 PRODUCT PORTFOLIO
14.21.3 RECENT DEVELOPMENT
14.22 NEURONANO AB
14.22.1 COMPANY SNAPSHOT
14.22.2 PRODUCT PORTFOLIO
14.22.3 RECENT DEVELOPMENTS
14.23 NEURIMPULSE S.R.L.
14.23.1 COMPANY SNAPSHOT
14.23.2 PRODUCT PORTFOLIO
14.23.3 RECENT DEVELOPMENTS
14.24 NEWRONIKA S.P.A.
14.24.1 COMPANY SNAPSHOT
14.24.2 PRODUCT PORTFOLIO
14.24.3 RECENT DEVELOPMENTS
14.25 OPTOGENTECH GMBH.
14.25.1 COMPANY SNAPSHOT
14.25.2 PRODUCT PORTFOLIO
14.25.3 RECENT DEVELOPMENTS
14.26 ONWARD
14.26.1 COMPANY SNAPSHOT
14.26.2 PRODUCT PORTFOLIO
14.26.3 RECENT DEVELOPMENT
14.27 STIMWAVE LLC (2021)
14.27.1 COMPANY SNAPSHOT
14.27.2 PRODUCT PORTFOLIO
14.27.3 RECENT DEVELOPMENTS
14.28 SEQUANA MEDICAL NV (2021)
14.28.1 COMPANY SNAPSHOT
14.28.2 REVENUE ANALYSIS
14.28.3 PRODUCT PORTFOLIO
14.28.4 RECENT DEVELOPMENTS
14.29 VALENCIA TECHNOLOGIES
14.29.1 COMPANY SNAPSHOT
14.29.2 PRODUCT PORTFOLIO
14.29.3 RECENT DEVELOPMENTS
15 QUESTIONNAIRE
16 RELATED REPORTS
表格列表
TABLE 1 NORTH AMERICA PREVALENCE OF OBESITY
TABLE 2 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA SPINAL CORD STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA SPINAL CORD STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA BATTERY IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA BATTERY IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 7 NORTH AMERICA BATTERY IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 8 NORTH AMERICA LEAD IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA LEAD IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 10 NORTH AMERICA LEAD IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 11 NORTH AMERICA SPINAL CORD STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA DEEP BRAIN STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA DEEP BRAIN STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA DEEP BRAIN STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 15 NORTH AMERICA DEEP BRAIN STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 16 NORTH AMERICA BATTERY IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 17 NORTH AMERICA BATTERY IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 18 NORTH AMERICA BATTERY IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 19 NORTH AMERICA DEEP BRAIN STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 20 NORTH AMERICA SACRAL NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, 2020-2029 (USD MILLION)
TABLE 21 NORTH AMERICA SACRAL NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 22 NORTH AMERICA SACRAL NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 23 NORTH AMERICA SACRAL NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 24 NORTH AMERICA SACRAL NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 25 NORTH AMERICA VAGUS NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, 2020-2029 (USD MILLION)
TABLE 26 NORTH AMERICA VAGUS NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 27 NORTH AMERICA VAGUS NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 28 NORTH AMERICA VAGUS NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 29 NORTH AMERICA VAGUS NERVE STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 30 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, 2020-2029 (USD MILLION)
TABLE 31 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 32 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 33 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 34 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 35 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 36 NORTH AMERICA DIRECT TENDER IN INTERNAL NEUROSTIMULATION DEVICES MARKET, BY REGION, 2020-2029 (USD MILLION)
TABLE 37 NORTH AMERICA THIRD PARTY PROVIDER IN INTERNAL NEUROSTIMULATION DEVICES MARKET, 2020-2029 (USD MILLION)
TABLE 38 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 39 NORTH AMERICA NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 40 NORTH AMERICA SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 41 NORTH AMERICA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 42 NORTH AMERICA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 43 NORTH AMERICA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 44 NORTH AMERICA LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 45 NORTH AMERICA LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 46 NORTH AMERICA LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 47 NORTH AMERICA SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 48 NORTH AMERICA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 49 NORTH AMERICA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 50 NORTH AMERICA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 51 NORTH AMERICA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 52 NORTH AMERICA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 53 NORTH AMERICA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 54 NORTH AMERICA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 55 NORTH AMERICA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 56 NORTH AMERICA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 57 NORTH AMERICA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 58 NORTH AMERICA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 59 NORTH AMERICA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 60 NORTH AMERICA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 61 NORTH AMERICA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 62 NORTH AMERICA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 63 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 64 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 65 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 66 NORTH AMERICA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 67 NORTH AMERICA NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 68 U.S. NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 69 U.S. SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 70 U.S. BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 71 U.S. BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 72 U.S. BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 73 U.S. LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 74 U.S. LEAD IN N NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 75 U.S. LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 76 U.S. SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 77 U.S. DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 78 U.S. DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 79 U.S. DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 80 U.S. BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 81 U.S. BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 82 U.S. BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 83 U.S. DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 84 U.S. SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 85 U.S. SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 86 U.S. SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 87 U.S. SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 88 U.S. VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 89 U.S. VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 90 U.S. VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 91 U.S. VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 92 U.S. GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 93 U.S. GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 94 U.S. GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 95 U.S. GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 96 U.S. NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 97 CANADA NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 98 CANADA SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 99 CANADA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 100 CANADA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 101 CANADA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 102 CANADA LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 103 CANADA LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 104 CANADA LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 105 CANADA SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 106 CANADA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 107 CANADA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 108 CANADA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 109 CANADA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 110 CANADA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 111 CANADA BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 112 CANADA DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 113 CANADA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 114 CANADA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 115 CANADA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 116 CANADA SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 117 CANADA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 118 CANADA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 119 CANADA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 120 CANADA VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 121 CANADA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 122 CANADA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (ASP)
TABLE 123 CANADA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (UNITS)
TABLE 124 CANADA GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 125 CANADA NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
TABLE 126 MEXICO NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 127 MEXICO SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 128 MEXICO BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 129 MEXICO BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 130 MEXICO BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 131 MEXICO LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 132 MEXICO LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 133 MEXICO LEAD IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 134 MEXICO SPINAL CORD STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 135 MEXICO DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 136 MEXICO DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 137 MEXICO DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 138 MEXICO BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (USD MILLION)
TABLE 139 MEXICO BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 140 MEXICO BATTERY IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 141 MEXICO DEEP BRAIN STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 142 MEXICO SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 143 MEXICO SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 144 MEXICO SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 145 MEXICO SACRAL NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 146 MEXICO VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 147 MEXICO VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 148 MEXICO VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 149 MEXICO VAGUS NERVE STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 150 MEXICO GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 151 MEXICO GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (ASP)
TABLE 152 MEXICO GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY PRODUCT TYPE, 2020-2029 (UNITS)
TABLE 153 MEXICO GASTRIC ELECTRICAL STIMULATION IN NEUROSTIMULATION DEVICES MARKET, BY APPLICATION, 2020-2029 (USD MILLION)
TABLE 154 MEXICO NEUROSTIMULATION DEVICES MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)
图片列表
FIGURE 1 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: GEOGRAPHIC SCOPE
FIGURE 3 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: DATA TRIANGULATION
FIGURE 4 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: SNAPSHOT
FIGURE 5 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BOTTOM UP APPROACH
FIGURE 6 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: TOP DOWN APPROACH
FIGURE 7 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: INTERVIEWS BY REGION AND DESIGNATION
FIGURE 8 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: THE CATEGORY VS TIME GRID
FIGURE 10 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET SEGMENTATION
FIGURE 11 INCREASE IN PREVALENCE AND INCIDENCE OF NEUROLOGICAL DISEASES AND DEMAND FOR INTERNAL NEUROSTIMULATION DEVICES AS A ADD ON THERAPY ARE EXPECTED TO DRIVE THE NORTH AMERICA INTERNAL NEUROSTIMULATIOJ DEVICES MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 SPINAL CORD STIMULATION IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET IN 2022 TO 2029
FIGURE 13 NORTH AMERICA INCIDENCE OF ISCHEMIA
FIGURE 14 NORTH AMERICA INCIDENCE OF PARKINSON'S DISEASES
FIGURE 15 NORTH AMERICA INCIDENCE OF TREMOR
FIGURE 16 NORTH AMERICA INCIDENCE RATE OF EPILEPSY
FIGURE 17 NORTH AMERICA INCIDENCE RATE OF GASTROPARESIS
FIGURE 18 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET
FIGURE 19 INCIDENCE OF ADULT ONSET BRAIN DISORDERS IN THE U.S. IN 2021
FIGURE 20 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY PRODUCT TYPE, 2021
FIGURE 21 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION)
FIGURE 22 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY PRODUCT TYPE, CAGR (2022-2029)
FIGURE 23 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 24 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2021
FIGURE 25 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)
FIGURE 26 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)
FIGURE 27 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 28 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: SNAPSHOT (2021)
FIGURE 29 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY COUNTRY (2021)
FIGURE 30 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY COUNTRY (2022 & 2029)
FIGURE 31 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY COUNTRY (2021 & 2029)
FIGURE 32 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: BY PRODUCT TYPE (2022-2029)
FIGURE 33 NORTH AMERICA INTERNAL NEUROSTIMULATION DEVICES MARKET: COMPANY SHARE 2021 (%)
研究方法
数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外,市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息,请请求分析师致电或下拉您的询问。
DBMR 研究团队使用的关键研究方法是数据三角测量,其中包括数据挖掘、数据变量对市场影响的分析和主要(行业专家)验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息,请向我们的行业专家咨询。
可定制
Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制,包括目标品牌的价格趋势分析、了解其他国家的市场(索取国家列表)、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表(事实手册)中的数据,或者可以帮助您根据报告中的数据集创建演示文稿。
